论文部分内容阅读
[目的]评价胃肠起搏联合莫沙必利及复方消化酶治疗功能性消化不良(functional dyspepsia,FD)的有效性。[方法]将140例FD患者根据自愿原则随机分为试验组与对照组,每组70例;对照组口服莫沙必利及复方消化酶胶囊,试验组在服药的基础上加用WHC泰士胃肠起搏器治疗,疗程均为2周;对2组治疗前后进行消化道症状评分。[结果]试验组消化道症状积分下降显著高于对照组;试验组总有效率87.1%,对照组总有效率61.4%,2组比较差异有统计学意义(P<0.05);2组患者均未发现严重不良反应。[结论]胃肠起搏联合莫沙必利及复方消化酶治疗FD的临床疗效明显,优于服用莫沙必利及复方消化酶。
[Objective] To evaluate the effectiveness of gastrointestinal pacing combined with mosapride and compound digestive enzymes in the treatment of functional dyspepsia (FD). [Methods] According to the voluntary principle, 140 cases of FD patients were randomly divided into experimental group and control group with 70 cases in each group. The control group was orally given mosapride and compound digestive enzyme capsules. The experimental group was given WHC Taishiwei Intestinal pacemaker treatment, treatment were 2 weeks; 2 groups before and after treatment of gastrointestinal symptoms score. [Results] The score of gastrointestinal symptoms in the experimental group was significantly lower than that in the control group. The total effective rate was 87.1% in the experimental group and 61.4% in the control group. There was significant difference between the two groups (P <0.05) No serious adverse reactions were found. [Conclusion] The clinical efficacy of gastrointestinal pacing combined with mosapride and compound digestive enzymes in the treatment of FD is better than taking mosapride and compound digestive enzymes.